SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?

被引：3
|
作者：
Cervantes, Carlos Escobar [1 ]
机构：
[1] Univ Hosp La Paz, Cardiol Dept, Madrid 28046, Spain
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2024年 / 12卷 / 08期
关键词：
D O I：
10.1016/S2213-8587(24)00183-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [21] SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
    Mone, Pasquale
    Ciccarelli, Michele
    Jankauskas, Stanislovas S.
    Guerra, Germano
    Vecchione, Carmine
    Visco, Valeria
    Santulli, Gaetano
    LANCET HEALTHY LONGEVITY, 2024, 5 (09):
  • [22] Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Li, Jiahua
    Albajrami, Oltjon
    Zhuo, Min
    Hawley, Chelsea E.
    Paik, Julie M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (11): : 1678 - 1688
  • [23] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [24] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [25] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [26] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [27] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [28] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [29] Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
    Olanrewaju, Olusegun A.
    Sheeba, Fnu
    Kumar, Avinash
    Ahmad, Saad
    Blank, Narendar
    Kumari, Reema
    Kumari, Komal
    Salame, Tamara
    Khalid, Ayesha
    Yousef, Nazdar
    Varrassi, Giustino
    Khatri, Mahima
    Kumar, Satish
    Mohamad, Tamam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [30] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last? (vol 4, pg 963, 2016)
    Nauck, M. A.
    Meier, J. J.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : E8 - E8
12345